UiPath focuses on agentic automation, boasts a large ARR base, and has high gross margins. Click here to read why PATH stock ...

UiPath (PATH) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Despite a 20% stock decline, we maintain a bullish view on UiPath due to its strategic pivot to Agentic AI and strong ...

Both APP and PATH are technology companies leveraging artificial intelligence to enhance their platforms. Which one is a ...

Cathie Wood's Ark Invest sold shares in UiPath, Prime Medicine, and Repare Therapeutics, with notable gains and losses.

Learn more about whether Asana, Inc. or UiPath Inc. is a better investment based on AAII's A+ Investor grades, which compare ...

Learn more about whether UiPath Inc. or Qualys, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

UiPath's current-quarter and full-year outlooks came up short of estimates as the automated software maker warned of the impact of federal spending cuts and changes in the macroeconomic environment.

UiPath's non-GAAP (adjusted) earnings of $0.26 in the quarter were up 13% from the year-ago quarter and easily outpaced Wall Street's consensus estimate of $0.20 per share. But investors mostly ...

Cathie Wood’s ARK ETFs have made their latest round of daily trades for Wednesday, April 9th, 2025, continuing to adjust their positions in a variety of companies across their funds. The most ...

UiPath shares rise on launch of generative AI-based UiPath Medical Record Summarization agent at Google Cloud Next 2025.

Zacks.com users have recently been watching UiPath (PATH) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.